E1	Procedure:T1 Name:T2 Temporality:E38
E3	Condition:T3 Name:T4
E5	Procedure:T5 Name:T6 Temporality:E54
E7	Condition:T7 Name:T8
E8	Eq-Comparison:T22 Operator:T9 Value:T17
E9	Eq-Comparison:T23 Operator:T10 Temporal-Unit:T14 Value:T18
E10	Eq-Comparison:T24 Operator:T11 Temporal-Unit:T15 Value:T19
E11	Eq-Comparison:T25 Operator:T12 Value:T20 Unit:T67
E12	Eq-Comparison:T26 Operator:T13 Temporal-Unit:T16 Value:T21
E2	Condition:T27 Name:T28 Severity:T36
E4	Condition:T29 Name:T30
E13	Modifier:T33 Modifies:E2
E14	Modifier:T34 Modifies:E2
E16	Procedure:T37 Name:T38
E17	Procedure:T39 Name:T40 Temporality:E18 Minimum-Count:E8
E18	Eq-Comparison:T41 Temporal-Period:T42
E19	Modifier:T43 Modifies:E1
E20	Condition:T44 Name:T48
E21	Condition:T45 Name:T50
E22	Condition:T46 Name:T49
E23	Observation:T47 Name:T51
E25	Procedure:T53 Name:T54 Temporality:E39
E26	Procedure:T55 Temporality:E42
E27	Drug:T57 Name:T58
E28	Drug:T59 Name:T60
E30	Drug:T63
E31	Modifier:T65 Modifies:E30
E32	Study:T66 Study-Of:E49
E33	Procedure:T68
E35	Drug:T70 Temporality:E56
E6	Modifier:T31
E36	Modifier:T32 Modifies:T30
E38	Eq-Comparison:T73 Temporal-Recency:T74
E39	Eq-Comparison:T75 Temporal-Recency:T76
E40	Assertion:T77 Asserted:E25
E42	Eq-Comparison:T79 Temporal-Period:T80
E43	Modifier:T56 Modifies:T58
E44	Study:T81 Study-Of:E29
E45	Other:T82 Is-Other:E44
E29	Procedure:T61 Temporality:E10
E46	Drug:T62
E47	Eq-Comparison:T83 Temporal-Recency:T84
E49	Drug:T86 Temporality:E47
E50	Condition:T64 Name:T87
E51	Assertion:T88 Asserted:E7 Asserted2:E3
E52	Assertion:T89 Asserted:E33
E54	Eq-Comparison:T91 Temporal-Period:T92
E56	Eq-Comparison:T71 Temporal-Recency:T94
T1	Procedure 303 323	chemotherapy regimen
T2	Procedure-Name 303 323	chemotherapy regimen
T3	Condition 763 779	pleural effusion
T4	Condition-Name 763 779	pleural effusion
T5	Procedure 825 841	ascites drainage
T6	Procedure-Name 825 841	ascites drainage
T7	Condition 747 761	cancer ascites
T8	Condition-Name 747 761	cancer ascites
T9	Eq-Operator 175 176	≥
T10	Eq-Operator 384 385	≤
T11	Eq-Operator 574 580	within
T12	Eq-Operator 623 624	<
T13	Eq-Operator 842 848	within
T14	Eq-Temporal-Unit 387 392	weeks
T15	Eq-Temporal-Unit 583 588	weeks
T16	Eq-Temporal-Unit 851 857	months
T17	Eq-Value 176 177	2
T18	Eq-Value 385 386	8
T19	Eq-Value 581 582	4
T20	Eq-Value 625 626	5
T21	Eq-Value 849 850	2
T22	Eq-Comparison 175 177	≥2
T23	Eq-Comparison 384 392	≤8 weeks
T24	Eq-Comparison 574 588	within 4 weeks
T25	Eq-Comparison 622 649	(< 5 elimination half-lives
T26	Eq-Comparison 842 857	within 2 months
T27	Condition 92 98	cancer
T28	Condition-Name 92 98	cancer
T29	Condition 148 154	cancer
T30	Condition-Name 148 154	cancer
T33	Modifier 71 91	endometrioid ovarian
T34	Modifier 61 67	serous
T36	Severity 50 60	high-grade
T37	Procedure 25 39	Histologically
T38	Procedure-Name 25 39	Histologically
T39	Procedure 187 215	platinum-containing regimens
T40	Procedure-Name 187 215	platinum-containing regimens
T41	Eq-Comparison 178 186	previous
T42	Eq-Temporal-Period 178 186	previous
T43	Modifier 288 302	platinum-based
T44	Condition 221 238	Complete response
T45	Condition 247 263	partial response
T46	Condition 240 242	CR
T47	Observation 265 267	PR
T48	Condition-Name 221 238	Complete response
T49	Condition-Name 240 242	CR
T50	Condition-Name 247 263	partial response
T51	Observation-Name 265 267	PR
T53	Procedure 412 420	platinum
T54	Procedure-Name 412 420	platinum
T55	Procedure 452 461	treatment
T57	Drug 469 497	poly (ADP-ribose) polymerase
T58	Drug-Name 469 497	poly (ADP-ribose) polymerase
T59	Drug 499 503	PARP
T60	Drug-Name 499 503	PARP
T63	Drug 699 704	drugs
T65	Modifier 668 686	molecular targeted
T66	Study 657 662	study
T67	Eq-Unit 639 649	half-lives
T68	Procedure 793 801	drainage
T70	Drug 877 891	administration
T31	Modifier 110 128	primary peritoneal
T32	Modifier 133 147	fallopian tube
T73	Eq-Comparison 283 287	last
T74	Eq-Temporal-Recency 283 287	last
T75	Eq-Comparison 399 403	last
T76	Eq-Temporal-Recency 399 403	last
T77	Assertion 359 369	Ability to
T79	Eq-Comparison 446 451	Prior
T80	Eq-Temporal-Period 446 451	Prior
T56	Modifier 505 514	inhibitor
T81	Study 553 558	study
T82	Other 547 552	other
T61	Procedure 564 573	treatment
T62	Drug 559 563	drug
T83	Eq-Comparison 602 607	first
T84	Eq-Temporal-Recency 602 607	first
T86	Drug 663 667	drug
T64	Condition 692 698	cancer
T87	Condition-Name 692 698	cancer
T88	Assertion 735 743	symptoms
T89	Assertion 785 789	need
T91	Eq-Comparison 815 824	undergone
T92	Eq-Temporal-Period 815 824	undergone
T71	Eq-Comparison 871 876	first
T94	Eq-Temporal-Recency 871 876	first
A1	Eq-Operator-Value T9 GTEQ
A2	Eq-Operator-Value T10 LTEQ
A3	Eq-Operator-Value T11 LTEQ
A4	Eq-Operator-Value T12 LT
A5	Eq-Operator-Value T13 LTEQ
A6	Eq-Temporal-Unit-Value T14 week
A7	Eq-Temporal-Unit-Value T15 week
A8	Eq-Temporal-Unit-Value T16 month
A9	Severity-Value T36 severe
A11	Eq-Temporal-Period-Value T42 past
A10	Eq-Temporal-Recency-Value T74 most-recent-time
A13	Eq-Temporal-Recency-Value T76 most-recent-time
A14	Assertion-Type-Value E40 hypothetical
A16	Eq-Temporal-Period-Value T80 past
A17	Eq-Temporal-Recency-Value T84 first-time
A19	Assertion-Type-Value E51 possible
A20	Assertion-Type-Value E52 hypothetical
A21	Eq-Temporal-Period-Value T92 past
A22	Eq-Temporal-Recency-Value T94 first-time
R2	Example-Of Arg1:E4 Arg2:E2
R3	Found-By Arg1:E2 Arg2:E16
R4	Abbrev-Of Arg1:E22 Arg2:E20
R5	Abbrev-Of Arg1:E23 Arg2:E21
R6	Using Arg1:E21 Arg2:E1
R7	Using Arg1:E20 Arg2:E1
R8	Using Arg1:E26 Arg2:E27
R9	Abbrev-Of Arg1:E28 Arg2:E27
R1	Using Arg1:E29 Arg2:E46
R10	Equivalent-To Arg1:E11 Arg2:E47
R11	Treatment-For Arg1:E30 Arg2:E50
R12	Example-Of Arg1:E30 Arg2:E49
R13	Or Arg1:E14 Arg2:E13
R14	Or Arg1:E20 Arg2:E21
R15	Before Arg1:E5 Arg2:E56
R16	Or Arg1:E6 Arg2:E36
R17	After Arg1:E9 Arg2:E39
R18	Before Arg1:E10 Arg2:E47
R19	And Arg1:E3 Arg2:E52
R20	Or Arg1:E33 Arg2:E5
R21	Or Arg1:E7 Arg2:E3